Letrozole was first introduced by Novartis Pharmaceuticals Corp in its drug Femara on Jul 25, 1997. 19 different companies have introduced drugs containing Letrozole.
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on
Letrozole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Several generic applications have been filed for Letrozole. The first generic version for Letrozole was by Pharmobedient Consulting Llc and was approved on Dec 24, 2008. And the latest generic version is by Zydus Lifesciences Global Fze and was approved on Sep 14, 2026.
Given below is the list of companies who have filed for
Letrozole generic, along with the locations of their manufacturing plants worldwide.
